BMJ  2008;336:610-612 (15 March), doi:10.1136/bmj.39498.525706.AD

Practice

Guidelines

Diagnosis and treatment of prostate cancer: summary of NICE guidance

¹ Taunton & Somerset NHS Foundation Trust, Musgrove Park Hospital, Taunton TA1 5DA, ² Leeds Teaching Hospitals NHS Trust, St James’s University Hospital, Leeds LS9 7TF , ³ National Collaborating Centre for Cancer, Cardiff CF10 3AF

The first 150 words of the full text of this article appear below.

Why read this summary?

Prostate cancer is one of the commonest cancers in men. Each year there are about 35 000 new cases in England and Wales and over 9000 deaths. The clinical course can extend over many years and often involves many different healthcare professionals. Evidence exists of practice variation around the country and of patchy availability of certain treatments and procedures. This article highlights a selection of the most recent recommendations from the National Institute for Health and Clinical Excellence (NICE) on the diagnosis and treatment of prostate cancer.¹

Recommendations

NICE recommendations are based on systematic reviews of the best available evidence. When minimal evidence is available, recommendations are based on the guideline development group’s opinion of what constitutes good practice. Evidence levels for the recommendations are given in italic in square brackets.

Informed decision making
Men with prostate cancer can be faced with multiple treatment choices over many years. Healthcare professionals should:

• Adequately inform men . . . [Full text of this article]

Diagnosis
Localised disease
Low risk
Intermediate risk
High risk
Relapse after radical treatment
Hormonal therapy
Hormone refractory disease and palliative care
Bone metastases
Treatment complications
Follow-up
Overcoming barriers
Further information on the guidance
Background
Methods
Future research

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

Related Article

Commentary: controversies in NICE guidance on prostate cancer

Timothy J Wilt
BMJ 2008 336: 612-614. [Extract] [Full Text] [PDF]

Rapid Responses:

Read all Rapid Responses

BAUS Comments on Diagnosis and treatment of prostate cancer: summary of NICE guidance

Anthony R Mundy, et al.
bmj.com, 19 Mar 2008 [Full text]

NICE guidance on prostate cancer and the role of active surveillance for low risk, localised disease

Howard P Marsh, et al.
bmj.com, 25 Mar 2008 [Full text]

Response to BAUS Comments

John Graham, et al.
bmj.com, 8 Apr 2008 [Full text]

Surveillance guideline goes too far

Laurence Klotz
bmj.com, 29 Apr 2008 [Full text]